title: European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.
abstract: BACKGROUND
  Metabolic diseases are frequently observed in HIV-infected persons and, as the risk of contracting these diseases is age-related, their prevalence will increase in the future as a consequence of the benefits of antiretroviral therapy (ART).
  All HIV-infected persons should be screened at regular intervals for a history of metabolic disease, dyslipidaemia, diabetes mellitus, hypertension and alteration of body composition; cardiovascular risk and renal function should also be assessed. Efforts to prevent cardiovascular disease will vary in intensity depending on an individual's absolute risk of ischaemic heart disease and should be comprehensive in nature. Lifestyle interventions should focus on counselling to stop smoking, modify diet and take regular exercise. A healthy diet, exercise and maintaining normal body weight tend to reduce dyslipidaemia; if not effective, a change of ART should be considered, followed by use of lipid-lowering medication in high-risk patients. A pre-emptive switch from thymidine analogues is recommended to reduce the risk of development or progression of lipoatrophy. Intra-abdominal fat accumulation is best managed by exercise and diet. Prevention and management of type 2 diabetes mellitus and hypertension follow guidelines used in the general population. When using medical interventions to prevent and/or treat metabolic disease(s), impairment of the efficacy of ART should be avoided by considering the possibility of pharmacokinetic interactions and compromised adherence. Specialists in HIV and specialists in metabolic diseases should consult each other, in particular in difficult-to-treat cases.
  
  
  CONCLUSIONS
  Multiple and relatively simple approaches exist to prevent metabolic diseases in HIV-infected persons; priority should be given to patients at high risk of contracting these diseases.
authors.affiliation: Centre for Viral Diseases KMA, Rigshospitalet and Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. jdl@cphiv.dk
authors.forename: J D
authors.initials: JD
authors.lastname: Lundgren
authors.forename: M
authors.initials: M
authors.lastname: Battegay
authors.forename: G
authors.initials: G
authors.lastname: Behrens
authors.forename: S
authors.initials: S
authors.lastname: De Wit
authors.forename: G
authors.initials: G
authors.lastname: Guaraldi
authors.forename: C
authors.initials: C
authors.lastname: Katlama
authors.forename: E
authors.initials: E
authors.lastname: Martinez
authors.forename: D
authors.initials: D
authors.lastname: Nair
authors.forename: W G
authors.initials: WG
authors.lastname: Powderly
authors.forename: P
authors.initials: P
authors.lastname: Reiss
authors.forename: J
authors.initials: J
authors.lastname: Sutinen
authors.forename: A
authors.initials: A
authors.lastname: Vigano
mesh_terms: D002318:Cardiovascular Diseases / Q000150:complications / Q000517:prevention & control; D004347:Drug Interactions; D015658:HIV Infections / Q000150:complications / Q000517:prevention & control* / Q000628:therapy; D006801:Humans; D008019:Life Style; D008659:Metabolic Diseases / Q000150:complications / Q000517:prevention & control* / Q000628:therapy; D019338:Polypharmacy